RESUMEN
BACKGROUND AND AIM: COVID-19 is a global public health concern. As no standard treatment has been found for it yet, several minerals and vitamins with antioxidants, immunomodulators, and antimicrobials roles can be sufficient for the immune response against the disease. The present study evaluates the serum vitamin D, calcium, and Zinc levels in patients with COVID-19. MATERIALS & METHODS: This research is a case-control study performed in May 2020 on 93 patients with COVID-19 hospitalized in a Shoushtar city hospital and on 186 healthy subjects with no symptoms of COVID-19. The serum vitamin D, calcium, and zinc levels were collected and analyzed using correlation coefficient and independent t-test via SPSS 18. RESULTS: Vitamin D levels had a significant difference between the case and control groups (p = 0.008). Serum calcium and serum zinc levels also had statistically significant differences between the two groups (p < 0.001). CONCLUSION: The research results showed that serum zinc, calcium, and vitamin D levels in COVID-19 patients are lower than in the control group. The supplementation with such nutrients is a safe and low-cost measure that can help cope with the increased demand for these nutrients in risk of acquiring the COVID-19 virus.
Asunto(s)
COVID-19/sangre , Calcio/sangre , Enfermedades Carenciales/sangre , Estado Nutricional , Vitamina D/sangre , Zinc/sangre , Adulto , Antiinfecciosos/sangre , Antioxidantes/metabolismo , COVID-19/complicaciones , COVID-19/prevención & control , Calcio/deficiencia , Estudios de Casos y Controles , Ciudades , Enfermedades Carenciales/complicaciones , Enfermedades Carenciales/prevención & control , Suplementos Dietéticos , Femenino , Hospitalización , Hospitales , Humanos , Factores Inmunológicos/sangre , Irán , Masculino , Micronutrientes/sangre , Persona de Mediana Edad , Pandemias , SARS-CoV-2 , Población UrbanaRESUMEN
Polyphenols are plant secondary metabolites containing antioxidant properties, which help to protect chronic diseases from free radical damage. Dietary polyphenols are the subject of enhancing scientific interest due to their possible beneficial effects on human health. In the last two decades, there has been more interest in the potential health benefits of dietary polyphenols as antioxidant. Black soybeans (Glycine max L. Merr) are merely a black variety of soybean containing a variety of phytochemicals. These phytochemicals in black soybean (BSB) are potentially effective in human health, including cancer, diabetes, cardiovascular diseases, cerebrovascular diseases, and neurodegenerative diseases. Taking into account exploratory study, the present review aims to provide up-to-date data on health benefit of BSB, which helps to explore their therapeutic values for future clinical settings. All data of in vitro and in vivo studies of BSB and its impact on human health were collected from a library database and electronic search (Science Direct, PubMed, and Google Scholar). The different pharmacological information was gathered and orchestrated in a suitable spot on the paper.
Asunto(s)
Glycine max/química , Polifenoles/sangre , Polifenoles/farmacología , Animales , Antocianinas/sangre , Antocianinas/farmacología , Antiinfecciosos/sangre , Antiinfecciosos/farmacología , Antioxidantes/farmacología , Presión Sanguínea/efectos de los fármacos , Peso Corporal , Huesos/efectos de los fármacos , Modelos Animales de Enfermedad , Humanos , Neoplasias/prevención & control , Fitoquímicos/sangre , Fitoquímicos/farmacología , Extractos Vegetales/sangre , Extractos Vegetales/farmacologíaRESUMEN
A sensitive, specific and rapid ultra-high-pressure liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) method has been developed to investigate pharmacokinetic properties of psoralen and isopsoralen, two compounds isolated from raw/salt-processed fruit of Psoralea corylifolia L. UHPLC-MS/MS was used with positive ion electrospray. The mobile phase was composed of acetonitrile and 0.1% formic acid aqueous solution and a gradient elution program at flow rate of 0.3 mL/min was applied. Multiple reaction monitoring mode was used for the quantification of psoralen, isopsoralen ([M + H](+) m/z 187.0 â m/z 131.0) and scoparone (m/z 207.0 â m/z 151.1). Scoparone served as an internal standard. The method was fully validated for its sensitivity, selectivity, stability, matrix effect and extraction recovery. The obtained results showed that salt-processed Buguzhi significantly promoted the absorption of psoralen and isopsoralen, and increased the bioavailability of these compounds.
Asunto(s)
Medicamentos Herbarios Chinos/farmacocinética , Ficusina/farmacocinética , Furocumarinas/farmacocinética , Psoralea/química , Administración Oral , Animales , Antiinfecciosos/sangre , Antiinfecciosos/química , Antiinfecciosos/farmacocinética , Cromatografía Líquida de Alta Presión/métodos , Medicamentos Herbarios Chinos/administración & dosificación , Medicamentos Herbarios Chinos/química , Ficusina/sangre , Ficusina/química , Frutas/química , Furocumarinas/sangre , Furocumarinas/química , Límite de Detección , Masculino , Ratas Sprague-Dawley , Sales (Química)/química , Espectrometría de Masas en Tándem/métodosRESUMEN
BACKGROUND: Linezolid may be administered in combination with norfloxacin, gatifloxacin, levofloxacin, moxifloxacin, and tinidazole for the treatment of various infections, such as urinary and respiratory tract infections, to improve the efficacy of the treatment or to reduce the duration of therapy. Knowledge of the antibiotic plasma concentrations combined with bacterial susceptibility evaluated in terms of minimum inhibitory concentration would optimize treatment efficacy while limiting the risk of dose-related adverse effects and avoiding suboptimal concentrations. METHODS: A new high-performance liquid chromatography assay method was developed and validated for determination of the above-mentioned drugs in small samples of human plasma. After protein precipitation with acetonitrile:methanol (1:1, vol/vol), satisfactory separation was achieved on a Hypersil BDS C18 column (250 × 4.6 mm, 5 µm) using a mobile phase comprising 20 mM sodium dihydrogen phosphate-2 hydrate (pH = 3.2) and acetonitrile at a ratio of 75:25, vol/vol; the elution was isocratic at ambient temperature with a flow rate of 1.5 mL/min. The ultraviolet detector was set at 260 nm. The validated method was applied to assay real plasma samples used for pharmacokinetic studies and therapeutic drug monitoring of the selected drugs. RESULTS: The assay method described was found to be rapid, sensitive, reproducible, precise, and accurate. Linearity was demonstrated over the concentration ranges as follows: 0.1-30 µg/mL for linezolid and tinidazole; 0.05-5 µg/mL for norfloxacin; and 0.1-10 µg/mL for moxifloxacin, levofloxacin, and gatifloxacin (mean r = 0.9999, n = 12). The observed within- and between-day assay precisions were within 12.5%, whereas accuracy ranged between 92.0% and 112% for all the analytes. The lower limit of quantification was 0.1 µg/mL for all the analytes except norfloxacin which was 0.05 µg/mL. CONCLUSIONS: This assay method was valid within a wide range of plasma concentrations and may be proposed as a suitable method for pharmacokinetic studies, therapeutic drug monitoring implementation, and routine clinical applications, especially for some populations of patients who receive a combination of these drugs.
Asunto(s)
Antiinfecciosos/sangre , Cromatografía Líquida de Alta Presión/métodos , Monitoreo de Drogas/métodos , Acetamidas/sangre , Adulto , Compuestos Aza/sangre , Fluoroquinolonas/sangre , Gatifloxacina , Humanos , Levofloxacino/sangre , Límite de Detección , Linezolid , Masculino , Moxifloxacino , Norfloxacino/sangre , Oxazolidinonas/sangre , Quinolinas/sangre , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Tinidazol/sangre , Adulto JovenRESUMEN
Potential benefits of combination antibiotic therapy for the treatment of plague have never been evaluated. We compared the efficacy of a ciprofloxacin (CIN) and gentamicin (GEN) combination therapy with that of each antibiotic administered alone (i) against Yersinia pestis in vitro and (ii) in a mouse model of bubonic plague in which animals were intravenously injected with antibiotics for five days, starting at two different times after infection (44 h and 56 h). In vitro, the CIN+GEN combination was synergistic at 0.5x the individual drugs' MICs and indifferent at 1x- or 2x MIC. In vivo, the survival rate for mice treated with CIN+GEN was similar to that observed with CIN alone and slightly higher than that observed for GEN alone 100, 100 and 85%, respectively when treatment was started 44 h post challenge. 100% of survivors were recorded in the CIN+GEN group vs 86 and 83% in the CIN and GEN groups, respectively when treatment was delayed to 56 h post-challenge. However, these differences were not statistically significant. Five days after the end of treatment, Y. pestis were observed in lymph nodes draining the inoculation site (but not in the spleen) in surviving mice in each of the three groups. The median lymph node log(10) CFU recovered from persistently infected lymph nodes was significantly higher with GEN than with CIN (5.8 vs. 3.2, p = 0.04) or CIN+GEN (5.8 vs. 2.8, p = 0.01). Taken as the whole, our data show that CIN+GEN combination is as effective as CIN alone but, regimens containing CIN are more effective to eradicate Y. pestis from the draining lymph node than the recommended GEN monotherapy. Moreover, draining lymph nodes may serve as a reservoir for the continued release of Y. pestis into the blood - even after five days of intravenous antibiotic treatment.
Asunto(s)
Ciprofloxacina/uso terapéutico , Gentamicinas/uso terapéutico , Peste/tratamiento farmacológico , Peste/microbiología , Animales , Antiinfecciosos/sangre , Antiinfecciosos/farmacología , Carga Bacteriana/efectos de los fármacos , Ciprofloxacina/sangre , Ciprofloxacina/farmacología , Quimioterapia Combinada , Femenino , Gentamicinas/sangre , Gentamicinas/farmacología , Ganglios Linfáticos/efectos de los fármacos , Ganglios Linfáticos/microbiología , Ganglios Linfáticos/patología , Ratones , Pruebas de Sensibilidad Microbiana , Análisis de Supervivencia , Factores de Tiempo , Resultado del Tratamiento , Yersinia pestis/efectos de los fármacosRESUMEN
INTRODUCTION: ICH S7A and S7B guidelines recommend the use of conscious animals for assessment of non-clinical cardiovascular safety of new chemical entities prior to testing in humans. Protocol design and data analysis techniques can affect the quality of the data produced and can therefore ultimately influence the clinical management of cardiovascular risk. It is therefore essential to have an understanding of the magnitude of changes detectable and the clinical relevance of these changes. This paper describes the utilisation of "super-intervals" to analyse and interpret data obtained from our conscious telemetered dog cardiovascular safety protocol and reports the statistical power achieved to detect changes in various cardiovascular parameters. METHODS: Cardiovascular data from 18 dog telemetry studies were used to calculate the statistical power to detect changes in cardiovascular parameters. Each study followed a test compound versus vehicle cross-over experimental design with 24h monitoring (n=4). 1 min mean raw data from each individual animal was compressed into 15 min mean data for each dose group for visualisation. Larger summary periods, or "super-intervals", were then selected to best represent any observed cardiovascular effects whilst taking into account the pharmacokinetic profile of the drug e.g. intervals of 1 to 6, 7 to 14 and 14 to 22h post-dose. RESULTS: With this methodology and study design we predict, using the median percentile that our studies have 80% power to detect the following changes: HR (+/-10bpm), LV +dP/dt max (+/-375mmHg/s), MBP (+/-5mmHg) and QTc (+/-4ms). DISCUSSION: Super-intervals are a simple way to handle the high degree of natural variability seen with any ambulatory cardiovascular assessment and, in our hands, result in highly statistically powered studies. The ability of this model to detect cardiovascular changes of small, but biologically relevant, magnitude enables confident decision making around the cardiovascular safety of new chemical entities.
Asunto(s)
Antiinfecciosos/farmacología , Antihipertensivos/farmacología , Compuestos Aza/farmacología , Sistema Cardiovascular/efectos de los fármacos , Doxazosina/farmacología , Electrocardiografía/efectos de los fármacos , Quinolinas/farmacología , Animales , Antiinfecciosos/administración & dosificación , Antiinfecciosos/sangre , Antihipertensivos/administración & dosificación , Antihipertensivos/sangre , Compuestos Aza/administración & dosificación , Compuestos Aza/sangre , Presión Sanguínea/efectos de los fármacos , Estado de Conciencia , Interpretación Estadística de Datos , Perros , Relación Dosis-Respuesta a Droga , Doxazosina/administración & dosificación , Doxazosina/sangre , Evaluación Preclínica de Medicamentos , Fluoroquinolonas , Frecuencia Cardíaca/efectos de los fármacos , Síndrome de QT Prolongado/diagnóstico , Masculino , Modelos Animales , Modelos Estadísticos , Moxifloxacino , Quinolinas/administración & dosificación , Quinolinas/sangre , Telemetría , Factores de TiempoRESUMEN
BACKGROUND: Metronidazole is an important antimicrobial agent for the therapeutic management of periodontal diseases and dentoalveolar infections. As in other tissues, the metronidazole concentration in gingival crevicular fluid is about equal to the plasma level. Thus, we hypothesized that metronidazole is not actively transported into human gingival fibroblasts. METHODS: Using high performance liquid chromatography, the influences of extracellular metronidazole concentrations, temperature, pH, and inhibitors of transporters on the uptake of metronidazole by cultured human gingival fibroblasts were tested. RESULTS: Metronidazole was taken up rapidly by fibroblasts; the intracellular metronidazole concentration reached the extracellular level in 3 minutes at 37 degrees C and in 2 minutes at 4 degrees C. The uptake of metronidazole by human gingival fibroblasts was not saturable, and the intracellular metronidazole concentrations increased linearly with the extracellular level. Temperature and pH had no significant influence on the uptake of metronidazole by fibroblasts. Probenecid and adenine had no influence on the uptake of metronidazole by fibroblasts. These findings indicate that metronidazole uptake does not involve a transporter. Metronidazole bound rapidly to human gingival fibroblasts, but the cell-associated drug declined progressively until it reached a stable plateau in 15 minutes. CONCLUSIONS: Metronidazole rapidly entered human gingival fibroblasts via simple diffusion. Metronidazole easily reached the minimal inhibitory concentration in fibroblasts and gingiva. Given the fact that intracellular concentrations of metronidazole in other tissues and cells are also close to the plasma level, we speculate that metronidazole enters other tissues and cells via simple diffusion.
Asunto(s)
Antiinfecciosos/farmacocinética , Fibroblastos/metabolismo , Encía/metabolismo , Metronidazol/farmacocinética , Adenina/farmacología , Adyuvantes Farmacéuticos/farmacología , Adolescente , Antiinfecciosos/sangre , Proteínas de Transporte de Catión/antagonistas & inhibidores , Células Cultivadas , Cromatografía Líquida de Alta Presión , Difusión , Líquido Extracelular/metabolismo , Encía/citología , Humanos , Concentración de Iones de Hidrógeno , Líquido Intracelular/metabolismo , Masculino , Moduladores del Transporte de Membrana/farmacología , Metronidazol/sangre , Pruebas de Sensibilidad Microbiana , Probenecid/farmacología , Temperatura , Factores de TiempoRESUMEN
BACKGROUND AND OBJECTIVE: Intra-abdominal abscesses are usually polymicrobial and involve a variety of aerobic and anaerobic organisms. Thus, in addition to adequate drainage, empirical coverage with broad-spectrum antimicrobials is central to the management of such abscesses and an understanding of pharmacokinetic properties can be valuable when selecting antimicrobial agents. The present study examined the penetration of the fluoroquinolone antimicrobial moxifloxacin into abdominal abscess fluid in patients with an intra-abdominal abscess. METHODS: This was a non-randomized, open-label, single-centre trial. Eight patients with CT or ultrasound evidence of a localized intra-abdominal abscess requiring interventional drainage without signs of generalized peritonitis were considered suitable candidates for pharmacokinetic analysis. Each patient received a single dose of moxifloxacin 400 mg by intravenous infusion. Paired samples of blood and abscess fluid were collected over 24 hours for pharmacokinetic analysis. RESULTS: Following intravenous infusion, moxifloxacin penetrated and accumulated in intra-abdominal abscess fluid. The abscess fluid/plasma concentration ratio increased continuously from 0.083 (95% CI 0.047, 0.147) at 2 hours after administration to 1.66 (95% CI 0.935, 2.946) at 24 hours; concentrations in abscess fluid tended to exceed those in plasma after 12-24 hours. Half-life and mean residence time were longer in abscess fluid than in plasma, suggesting that moxifloxacin accumulates in abscess fluid. The abscess fluid/plasma concentration ratio continued to increase throughout the 24-hour sampling period, indicating that equilibrium between plasma and abscess fluid was not reached during this time. High intersubject variability for total moxifloxacin concentrations in intra-abdominal abscess fluid was noted, suggesting that abscess wall permeability is likely to be the parameter most strongly influencing moxifloxacin pharmacokinetics in abscess fluid. Comparison of the study results with data obtained from other in vitro studies suggested that abscess fluid concentrations above the minimum inhibitory concentrations for pathogens commonly isolated in intra-abdominal infections were maintained for approximately 8 hours after administration in this study. CONCLUSIONS: Moxifloxacin penetrates intra-abdominal abscesses after interventional drainage. Based on the pharmacokinetic data, moxifloxacin is a good candidate therapy for use in patients with intra-abdominal abscesses undergoing CT-guided percutaneous drainage and may also prove valuable in the general systemic management of intra-abdominal abscesses in the future.
Asunto(s)
Absceso Abdominal/terapia , Antiinfecciosos/farmacocinética , Compuestos Aza/farmacocinética , Líquidos Corporales/metabolismo , Quinolinas/farmacocinética , Absceso Abdominal/metabolismo , Absceso Abdominal/patología , Adulto , Anciano , Anciano de 80 o más Años , Análisis de Varianza , Antiinfecciosos/efectos adversos , Antiinfecciosos/sangre , Área Bajo la Curva , Compuestos Aza/administración & dosificación , Compuestos Aza/efectos adversos , Bradicardia/inducido químicamente , Drenaje/métodos , Femenino , Fluoroquinolonas , Semivida , Humanos , Inyecciones Intravenosas , Cinética , Masculino , Persona de Mediana Edad , Moxifloxacino , Quinolinas/administración & dosificación , Quinolinas/efectos adversos , Factores de Tiempo , Distribución Tisular , Tomografía Computarizada por Rayos X/métodosRESUMEN
The objective of this study was to evaluate a physiologically based pharmacokinetic (PBPK) approach for predicting the plasma concentration-time curves expected after intravenous administration of candidate drugs to rodents. The predictions were based on a small number of properties that were either calculated based on the structure of the candidate drug (octanol:water partition coefficient, ionization constant(s)) or obtained from the typical high-throughput screens implemented in the early drug discovery phases (fraction unbound in plasma and hepatic intrinsic clearance). The model was tested comparing the predicted and the observed pharmacokinetics of 45 molecules. This dataset included six known drugs and 39 drug candidates from different discovery programs, so that the performance of the model could be evaluated in a real discovery case scenario. The plasma concentration-time curves were predicted with good accuracy, the pharmacokinetic parameters being on average two- to three-fold of actual values. Multivariate analysis was used for identifying the candidate properties which were likely associated to biased predictions. The application of this approach was found useful for the prioritization of the in vivo pharmacokinetics screens and the design of the first-time-in-animal studies.
Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Modelos Biológicos , Farmacocinética , Acetamidas/sangre , Acetamidas/química , Acetamidas/farmacocinética , Algoritmos , Animales , Antiinfecciosos/sangre , Antiinfecciosos/química , Antiinfecciosos/farmacocinética , Antidepresivos/sangre , Antidepresivos/química , Antidepresivos/farmacocinética , Benzodiazepinas/sangre , Benzodiazepinas/química , Benzodiazepinas/farmacocinética , Cromanos/sangre , Cromanos/química , Cromanos/farmacocinética , Diltiazem/sangre , Diltiazem/química , Diltiazem/farmacocinética , Hipoglucemiantes/sangre , Hipoglucemiantes/química , Hipoglucemiantes/farmacocinética , Linezolid , Hígado/metabolismo , Ratones , Oxazolidinonas/sangre , Oxazolidinonas/química , Oxazolidinonas/farmacocinética , Análisis de Componente Principal , Ratas , Roedores , Tiazolidinedionas/sangre , Tiazolidinedionas/química , Tiazolidinedionas/farmacocinética , Distribución Tisular , Troglitazona , Zidovudina/sangre , Zidovudina/química , Zidovudina/farmacocinéticaRESUMEN
The spectrum of pathogens causing chronic bacterial prostatitis comprises Gram-negative, Gram-positive and atypical microorganisms. Because of its broad spectrum of activity, the group 4 fluoroquinolone moxifloxacin might be a suitable antibiotic for treatment of bacterial prostatitis. The aim of this prospective study was to investigate the penetration of moxifloxacin into prostatic tissue in patients with benign prostatic hyperplasia. Patients received a single dose of moxifloxacin 400 mg in an 1 hour lasting infusion (250 ml) for perioperative prophylaxis before undergoing transurethral resection of the prostate (TURP). Serum concentrations were determined in all patients before infusion, at the end of infusion (time point 0), 0.5, 1 and 2 h after the end of infusion. Patients were randomized for tissue sampling either 0, 0.5, 1 or 2 h after the end of infusion. At beginning of TURP approximately 1 g of tissue was sampled for analysis. Concentrations of moxifloxacin in serum and tissue were determined by HPLC. 39 patients were evaluated. Median serum and prostatic tissue concentrations peaked at 0 h (4.94 mg/ L and 8.50 mg/ kg, respectively). The lowest concentrations were quantified at 2 h after the end of infusion (2.46 mg/ L and 3.88 mg/ kg, respectively). The prostatic tissue concentrations of moxifloxacin were approximately twice as high as in corresponding serum. At the end of infusion the tissue and serum concentrations seemed to be already equilibrated, as their ratios did not differ significantly during the time of investigation. After an intravenous infusion of 400 mg the serum and prostatic tissue concentrations of moxifloxacin were well above the MIC values of most important prostatic pathogens. The high tissue/ serum ratio and the extended antibacterial spectrum suggests active concentration in the prostate which may translate into increased efficacy compared to group 2 and 3 fluoroquinolones in the treatment of chronic bacterial prostatitis.
Asunto(s)
Compuestos Aza/sangre , Compuestos Aza/farmacocinética , Próstata/química , Hiperplasia Prostática/cirugía , Prostatitis/prevención & control , Quinolinas/sangre , Quinolinas/farmacocinética , Resección Transuretral de la Próstata/métodos , Anciano , Anciano de 80 o más Años , Antiinfecciosos/sangre , Antiinfecciosos/farmacocinética , Antiinfecciosos/uso terapéutico , Profilaxis Antibiótica/métodos , Compuestos Aza/uso terapéutico , Disponibilidad Biológica , Fluoroquinolonas , Humanos , Masculino , Persona de Mediana Edad , Moxifloxacino , Próstata/efectos de los fármacos , Próstata/cirugía , Hiperplasia Prostática/sangre , Hiperplasia Prostática/tratamiento farmacológico , Prostatitis/sangre , Prostatitis/cirugía , Quinolinas/uso terapéuticoRESUMEN
Antimicrobial efficacy in orthopedic device infections is diminished because of bacterial biofilms which express tolerance to antibiotics. Recently, the use of high doses of levofloxacin with rifampin has been recommended for staphylococcal infections. In the present study, we evaluated the efficacy of levofloxacin at doses of 50 mg/kg/day and 100 mg/kg/day (mimicking the usual and high human doses of 500 mg/day and 750 to 1,000 mg/day, respectively) and compared it to that of to linezolid, cloxacillin, vancomycin, and rifampin in a rat tissue cage model of experimental foreign-body infection by Staphylococcus aureus. The antimicrobial efficacy in vitro (by MIC, minimum bactericidal concentration, and kill curves) for logarithmic- and stationary-phase bacteria was compared with the in vivo efficacy. In vitro bactericidal activity at clinically relevant concentrations was reached by all drugs except rifampin and linezolid in the log-phase studies but only by levofloxacin in the stationary-phase studies. The bacterial count decreases from in vivo tissue cage fluids (means) for levofloxacin at 50 and 100 mg/kg/day, rifampin, cloxacillin, vancomycin, linezolid, and controls, respectively, were: -1.24, -2.26, -2.1, -1.56, -1.47, -1.15, and 0.33 (all groups versus controls, P < 0.05). Levofloxacin at 100 mg/kg/day (area under the concentration-time curve/MIC ratio, 234) was the most active therapy (P = 0.03 versus linezolid). Overall, in vivo efficacy was better predicted by stationary-phase studies, in which it reached a high correlation coefficient even if the rifampin group was excluded (r = 0.96; P < 0.05). Our results, including in vitro studies with nongrowing bacteria, pharmacodynamic parameters, and antimicrobial efficacy in experimental infection, provide good evidence to support the use of levofloxacin at high doses (750 to 1,000 mg/day), as recently recommended for treating patients with orthopedic prosthesis infections.
Asunto(s)
Antibacterianos/farmacología , Reacción a Cuerpo Extraño , Levofloxacino , Meticilina/farmacología , Ofloxacino/farmacología , Staphylococcus aureus/efectos de los fármacos , Acetamidas/sangre , Acetamidas/farmacocinética , Acetamidas/farmacología , Acetamidas/uso terapéutico , Animales , Antibacterianos/sangre , Antibacterianos/farmacocinética , Antibacterianos/uso terapéutico , Antiinfecciosos/sangre , Antiinfecciosos/farmacocinética , Antiinfecciosos/farmacología , Antiinfecciosos/uso terapéutico , Cloxacilina/sangre , Cloxacilina/farmacocinética , Cloxacilina/farmacología , Cloxacilina/uso terapéutico , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Reacción a Cuerpo Extraño/tratamiento farmacológico , Reacción a Cuerpo Extraño/prevención & control , Humanos , Linezolid , Masculino , Meticilina/sangre , Meticilina/farmacocinética , Pruebas de Sensibilidad Microbiana , Ofloxacino/sangre , Ofloxacino/farmacocinética , Ofloxacino/uso terapéutico , Oxazolidinonas/sangre , Oxazolidinonas/farmacocinética , Oxazolidinonas/farmacología , Oxazolidinonas/uso terapéutico , Ratas , Ratas Wistar , Rifampin/sangre , Rifampin/farmacocinética , Rifampin/farmacología , Rifampin/uso terapéutico , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Estafilocócicas/prevención & control , Vancomicina/sangre , Vancomicina/farmacocinética , Vancomicina/farmacología , Vancomicina/uso terapéuticoRESUMEN
Thymi Herba (Thymus vulgaris, rubbed) was given as feed additive to weanling piglets. 3 concentrations (0.1%, 0.5%, 1%) were tested against a control group. Rectal swabs were collected weekly and were sent in for bacterial testing. The shedding of haemolysing E. coli was evaluated. There was no significant difference in the shedding of haemolysing E. coli between the 4 groups. Neither was there a difference in the distribution of the various serotypes. Thymol was detected in the blood plasma in all thyme groups. The increase in thymol level with greater amounts of thyme herb was significant. Three days after withdrawal of the feed additive no thymol levels were detected. The study results did not reveal any effects on haemolysing E. coli in the gut.
Asunto(s)
Antiinfecciosos/sangre , Infecciones por Escherichia coli/veterinaria , Fitoterapia/veterinaria , Extractos Vegetales/uso terapéutico , Enfermedades de los Porcinos/tratamiento farmacológico , Timol/sangre , Thymus (Planta)/química , Animales , Animales Recién Nacidos , Suplementos Dietéticos , Relación Dosis-Respuesta a Droga , Infecciones por Escherichia coli/tratamiento farmacológico , Distribución Aleatoria , Porcinos , Resultado del Tratamiento , DesteteRESUMEN
Moxifloxacin, a fluoroquinolone antibiotic associated with QT prolongation, has been recommended as a positive control by regulatory authorities to evaluate the sensitivity of both clinical and preclinical studies to detect small but significant increases in QT interval measurements. In this study, we investigated effects of moxifloxacin on the hERG current in HEK-293 cells, electrocardiograms in conscious telemetered dogs, and repolarization parameters and arrhythmogenic potentials in the arterially perfused rabbit ventricular wedge model. Moxifloxacin inhibited the hERG current with an IC50 of 35.7 microM. In conscious telemetered dogs, moxifloxacin significantly prolonged QTc at 30 and 90 mg kg(-1), with mean serum Cmax of 8.52 and 22.3 microg ml(-1), respectively. In the wedge preparation, moxifloxacin produced a concentration-dependent prolongation of the action potential duration, QT interval, and the time between peak and end of the T wave, an indicator for transmural dispersion of repolarization. Phase 2 early after-depolarizations were observed in one of five experiments at 30 microM and five of five experiments at 100 microM. The arrhythmogenic potential was also concentration-dependent, and 100 microM ( approximately 18-fold above the typical unbound Cmax exposure in clinical usage) appeared to have a high risk of inducing torsade de pointes (TdP). Our data indicated a good correlation among the concentration-response relationships in the three preclinical models and with the available clinical data. The lack of TdP report by moxifloxacin in patients without other risk factors might be attributable to its well-behaved pharmacokinetic profile and other dose-limiting effects.
Asunto(s)
Arritmias Cardíacas/inducido químicamente , Compuestos Aza/efectos adversos , Síndrome de QT Prolongado/inducido químicamente , Quinolinas/efectos adversos , Potenciales de Acción/efectos de los fármacos , Animales , Antiinfecciosos/efectos adversos , Antiinfecciosos/sangre , Antiinfecciosos/farmacocinética , Área Bajo la Curva , Arritmias Cardíacas/fisiopatología , Compuestos Aza/sangre , Compuestos Aza/farmacocinética , Línea Celular , Modelos Animales de Enfermedad , Perros , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos/métodos , Electrocardiografía/efectos de los fármacos , Canales de Potasio Éter-A-Go-Go/antagonistas & inhibidores , Canales de Potasio Éter-A-Go-Go/fisiología , Femenino , Fluoroquinolonas , Humanos , Síndrome de QT Prolongado/fisiopatología , Masculino , Moxifloxacino , Fenetilaminas/farmacología , Canales de Potasio de Rectificación Interna/antagonistas & inhibidores , Canales de Potasio de Rectificación Interna/fisiología , Quinolinas/sangre , Quinolinas/farmacocinética , Conejos , Sulfonamidas/farmacología , Telemetría/métodos , Resultado del TratamientoRESUMEN
The purpose of this study was to construct a population pharmacokinetic (PK) metabolism (MB) model to describe ciprofloxacin (C) concentrations in plasma and vitreous and aqueous humors in 26 patients. Ciprofloxacin was given as a 3-day oral prophylactic treatment to 26 patients before vitrectomy. Plasma, vitreous, and aqueous humor samples were collected from patients at different times on the day of surgery. Patients were phenotyped for CYP 1A2 activity using caffeine. Ciprofloxacin and caffeine concentrations were determined using validated HPLC assays. All concentrations of ciprofloxacin were simultaneously modeled using a four-compartment PK-MB model. Creatinine clearance and CYP 1A2 activity were modeled as surrogate markers of renal and hepatic clearances, respectively. Population PK was performed with IT2S, and simulations were performed with ADAPT-II. No eye infections were observed in any of the patients enrolled in the study, and there were only minimal effects on vitreous and aqueous concentrations after ocular drops were added to the oral treatments. The model that best described the concentrations of ciprofloxacin in serum and in aqueous and vitreous humor was a four-compartment PK linear model. Simulated AUCs of ciprofloxacin mean concentrations in the aqueous and vitreous humors were 17 +/- 9 and 10 +/- 8% of the systemic AUC, respectively. The terminal elimination half-life of the compound was (mean +/- SD) 5.0 +/- 2.8 hours. The apparent volume of distribution (Vss/F) was calculated to be 122.1 +/- 39.7 L. This PK-MB model may be very useful in optimizing treatments of various eye infections with ciprofloxacin. The results of this study suggest that giving ciprofloxacin orally for 2 days preceding surgery may prevent endophthalmitis from occurring, consequently abrogating the need for administering antibiotics via intraocular injections.
Asunto(s)
Antiinfecciosos/metabolismo , Antiinfecciosos/farmacocinética , Ciprofloxacina/metabolismo , Ciprofloxacina/farmacocinética , Administración Oral , Administración Tópica , Anciano , Antiinfecciosos/sangre , Humor Acuoso/metabolismo , Cromatografía Líquida de Alta Presión , Ciprofloxacina/sangre , Citocromo P-450 CYP1A2/genética , Citocromo P-450 CYP1A2/metabolismo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Modelos Biológicos , Soluciones Oftálmicas , Fenotipo , Factores de Tiempo , VitrectomíaRESUMEN
BACKGROUND: Antimicrobial resistance rates for Streptococcus pneumoniae continue to increase worldwide, and resistance to nearly every major class of antimicrobials used to treat pneumococcal infections has been reported. Gatifloxacin (GFLX) is one of the quinolones that have strong activity against S. pneumoniae. METHODS: We compared the bacteriological, pharmacological and histopathological effects of orally administered GFLX with those of levofloxacin (LVFX) and ciprofloxacin (CPFX) in a murine model of pneumonia caused by penicillin-resistant S. pneumoniae (PRSP). RESULTS: Treatment with GFLX resulted in a significant decrease in the number of viable bacteria (control, CPFX, LVFX, and GFLX: 6.48 +/- 0.36, 6.44 +/- 0.27, 5.51 +/- 0.15, and 4.89 +/- 0.28 log10 CFU/lung, respectively, mean +/- SD). A significant decrease in mortality was observed in the GFLX-treated group in comparison with the other groups. Histopathological examination revealed that inflammatory changes in GFLX-treated mice were less marked than in the other mice. CONCLUSION: Our results suggest that orally administered GFLX is effective in PRSP pneumonia. The pharmacokinetic profiles also reflected the effectiveness of GFLX.
Asunto(s)
Antibacterianos/uso terapéutico , Antiinfecciosos/uso terapéutico , Ciprofloxacina/uso terapéutico , Fluoroquinolonas/uso terapéutico , Levofloxacino , Pulmón/efectos de los fármacos , Ofloxacino/uso terapéutico , Neumonía Neumocócica/tratamiento farmacológico , Administración Oral , Animales , Antibacterianos/sangre , Antibacterianos/farmacocinética , Antiinfecciosos/sangre , Antiinfecciosos/farmacocinética , Ciprofloxacina/sangre , Ciprofloxacina/farmacocinética , Evaluación Preclínica de Medicamentos , Fluoroquinolonas/sangre , Fluoroquinolonas/farmacocinética , Gatifloxacina , Pulmón/metabolismo , Pulmón/patología , Ratones , Ratones Endogámicos CBA , Ofloxacino/sangre , Ofloxacino/farmacocinética , Resistencia a las Penicilinas , Neumonía Neumocócica/mortalidad , Tasa de SupervivenciaRESUMEN
We compared the effects of DQ-113, a new quinolone, to those of vancomycin (VCM) and teicoplanin (TEIC) in murine models of hematogenous pulmonary infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and VCM-insensitive S. aureus (VISA). The MICs of DQ-113, VCM, and TEIC for MRSA were 0.125, 1.0, and 0.5 microg/ml, respectively; and those for VISA were 0.25, 8.0, and 8.0 microg/ml, respectively. Treatment with DQ-113 resulted in a significant decrease in the number of viable bacteria in the lungs of the mice used in the MRSA infection model (counts in mice treated with DQ-113, VCM, and TEIC and control mice, 6.33 +/- 0.22, 7.99 +/- 0.14, 7.36 +/- 0.20, and 8.47 +/- 0.22 log10 CFU/lung [mean +/- standard error of the mean], respectively [P<0.01 for the group treated with DQ-113 compared with the group treated with VCM or TEIC or the untreated group]). Mice infected with VISA were pretreated with cyclophosphamide, and the survival rate was recorded daily for 10 days. At the end of this period, 90% of the DQ-113-treated mice were still alive, whereas only 45 to 55% of the mice in the other three groups were still alive (P<0.05 for the group treated with DQ-113 compared with the group treated with VCM or TEIC or the untreated group]). DQ-113 also significantly (P<0.05) reduced the number of viable bacteria in the lungs compared with those in the lungs of the other three groups (counts in mice treated with DQ-113, VCM, and TEIC and control mice, 5.76 +/- 0.39, 7.33 +/- 0.07, 6.90 +/- 0.21, and 7.44 +/- 0.17 log10 CFU/lung, respectively). Histopathological examination revealed milder inflammatory changes in DQ-113-treated mice than in the mice in the other groups. Of the antibiotics analyzed, the parameters of area under the concentration-time from 0 to 6 h (AUC(0-6))/MIC and the time that the AUC(0-6) exceeded the MIC were the highest for DQ-113. Our results suggest that DQ-113 is potent and effective for the treatment of hematogenous pulmonary infections caused by MRSA and VISA strains.
Asunto(s)
Antiinfecciosos/uso terapéutico , Patógenos Transmitidos por la Sangre , Enfermedades Pulmonares/tratamiento farmacológico , Resistencia a la Meticilina , Quinolonas/uso terapéutico , Infecciones Estafilocócicas/tratamiento farmacológico , Resistencia a la Vancomicina , Animales , Antibacterianos/uso terapéutico , Antiinfecciosos/administración & dosificación , Antiinfecciosos/sangre , Inyecciones Intraperitoneales , Pulmón/metabolismo , Pulmón/microbiología , Enfermedades Pulmonares/microbiología , Masculino , Ratones , Pruebas de Sensibilidad Microbiana , Quinolonas/administración & dosificación , Quinolonas/sangre , Infecciones Estafilocócicas/microbiología , Staphylococcus aureus/efectos de los fármacos , Teicoplanina/uso terapéutico , Vancomicina/uso terapéuticoRESUMEN
DQ-113 is a new quinolone with potent activity against gram-positive pathogens. The in vivo activity of DQ-113 against Streptococcus pneumoniae was compared with those of gatifloxacin and ciprofloxacin in a mouse model. For this purpose, two strains of S. pneumoniae were used: penicillin-susceptible S. pneumoniae (PSSP) and penicillin-resistant S. pneumoniae (PRSP). The survival rates of mice infected with PSSP and PRSP at 14 days after infection were 80% in the DQ-113-treated group and 0 to 10% in the other three groups. In murine infections caused by PSSP, the 50% effective doses (ED50s) of DQ-113, gatifloxacin, and ciprofloxacin were 6.0, 41.3, and 131.6 mg/kg, respectively. Against PRSP-caused pneumonia in mice, the ED50s of DQ-113, gatifloxacin, and ciprofloxacin were 7.6, 64.7, and 125.9 mg/kg, respectively. Compared with the other drugs, DQ-113 showed excellent therapeutic efficacy and eradicated viable bacteria in both PSSP- and PRSP-infected mice. The means +/- standard errors of the means of viable bacterium counts in the lungs of gatifloxacin-treated, ciprofloxacin-treated, and untreated control mice infected with PSSP were 2.91 +/- 0.34, 3.13 +/- 0.48, and 3.86 +/- 0.80 log10 CFU/ml, respectively. The same counts in mice infected with PRSP treated with the same three agents were 6.57 +/- 0.99, 6.54 +/- 0.40, and 7.17 +/- 0.43 log10 CFU/ml, respectively. DQ-113 significantly decreased the number of viable bacteria in the lungs compared with gatifloxacin and ciprofloxacin. Of the drugs analyzed, the pharmacokinetic-pharmacodynamic parameter of area under the concentration-time curve (AUC)/MIC ratio for DQ-113 was significantly higher than those for gatifloxacin and ciprofloxacin. Our results suggest that DQ-113 has potent in vivo efficacy against both PSSP and PRSP.
Asunto(s)
Antiinfecciosos/uso terapéutico , Neumonía Neumocócica/tratamiento farmacológico , Quinolonas/uso terapéutico , Animales , Antiinfecciosos/sangre , Antiinfecciosos/farmacocinética , Ciprofloxacina/uso terapéutico , Fluoroquinolonas/uso terapéutico , Gatifloxacina , Pulmón/metabolismo , Masculino , Ratones , Ratones Endogámicos CBA , Pruebas de Sensibilidad Microbiana , Resistencia a las Penicilinas , Neumonía Neumocócica/microbiología , Quinolonas/sangre , Quinolonas/farmacocinética , Análisis de SupervivenciaRESUMEN
Previous studies have demonstrated that the chelation interactions demonstrated between fluoroquinolones and antacids also occur when they are coadministered with mineral-fortified foods. This study was conducted to evaluate the bioequivalence of levofloxacin when administered in a fasting state as compared to when it was administered with a common breakfast of calcium-fortified orange juice and ready-to-eat cereal. Fourteen of 16 healthy volunteers completed this study and received 500 mg of levofloxacin with each of the following: (1) 12 ounces of water, (2) subject-measured portions of juice and cereal, and (3) subject-measured portions of juice and cereal with milk. Plasma samples were collected prior to dosing and for up to 48 hours after. The results demonstrated that neither fed phase was bioequivalent to the fasting arm in terms of Cmax (with milk, 79.2% [72.6%, 85.7%]; without milk, 79.1% [73.3%, 84.9%]). In addition, a weak correlation was identified between the amount of change in 24-hour exposure and mineral fortification. The results of this study further demonstrate a need to require additional fed-fasted bioequivalence studies for drugs that demonstrate no interaction with the FDA meal but have significant interactions with drugs or supplements that contain large amounts of multivalent ions.
Asunto(s)
Antiinfecciosos/farmacocinética , Calcio de la Dieta/administración & dosificación , Alimentos Fortificados , Interacciones Alimento-Droga , Levofloxacino , Ofloxacino/farmacocinética , Adulto , Animales , Antiinfecciosos/administración & dosificación , Antiinfecciosos/sangre , Bebidas , Citrus , Estudios Cruzados , Grano Comestible , Ayuno , Femenino , Humanos , Masculino , Persona de Mediana Edad , Leche , Ofloxacino/administración & dosificación , Ofloxacino/sangre , Equivalencia TerapéuticaRESUMEN
Current estimates of the mortality associated with brain abscesses range from 0-24%, with neurological sequellae in 30-55% of survivors. Although the incidence of brain abscess appears to be increasing, likely due to an increase in the population of immunosuppressed patients, the condition is still sufficiently uncommon to make human clinical trials of therapy problematic. An animal model to study the efficacy of new treatment regimens, specifically, new antimicrobial agents is therefore necessary. This study uses a well-defined experimental paradigm as an inexpensive method of inducing and studying the efficacy of antibiotics in brain abscess. The rat model of brain abscess/cerebritis developed at this institution was used to determine the relative efficacy of trovafloxacin as compared to ceftriaxone in animals infected with Staphylococcus aureus. S. aureus ( approximately 10(5) CFU in 1 microliter) was injected with a Hamilton syringe, very slowly, over the course of 70 minutes after a two mm burr hole was created with a spherical carbide drill just posterior to the coronal suture and four mm lateral to the midline. Eighteen hours later treatment was begun; every 8 hours the rats were dosed with subcutaneous ceftriaxone (n = 10), trovafloxacin (n = 11) or 0.9% sterile pyogen-free saline (n = 10). After four days of treatment the brains were removed and sectioned with a scalpel. The entire injected hemisphere was homogenized and quantitative cultures performed. The mean +/- SEM log(10) colony forming units/ml S. aureus recovered from homogenized brain were as follows: controls 6.10 +/- 0.28; ceftriaxone 3.43 +/- 0.33; trovafloxacin 3.65 +/- 0.3. There was no significant difference in bacterial clearance between ceftriaxone versus trovafloxacin (p = 0.39). Trovafloxacin or other quinolones may provide a viable alternative to intravenous antibiotics in patients with brain abscess/cerebritis.
Asunto(s)
Antibacterianos/uso terapéutico , Antiinfecciosos/uso terapéutico , Absceso Encefálico/tratamiento farmacológico , Ceftriaxona/uso terapéutico , Fluoroquinolonas , Naftiridinas/uso terapéutico , Infecciones Estafilocócicas/tratamiento farmacológico , Animales , Antibacterianos/administración & dosificación , Antibacterianos/sangre , Antiinfecciosos/administración & dosificación , Antiinfecciosos/sangre , Área Bajo la Curva , Absceso Encefálico/microbiología , Ceftriaxona/administración & dosificación , Ceftriaxona/sangre , Modelos Animales de Enfermedad , Femenino , Semivida , Inyecciones Subcutáneas , Pruebas de Sensibilidad Microbiana , Naftiridinas/administración & dosificación , Naftiridinas/sangre , Ratas , Ratas Wistar , Infecciones Estafilocócicas/microbiología , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/aislamiento & purificaciónRESUMEN
Chelation interactions between drugs/supplements that contain large amounts of multivalent ions and the fluoroquinolones have been known for quite some time. However, there has been a lack of taking this interaction into account when they may be coadministered with foods that have been fortified with amounts of multiple multivalent ions that equal or exceed many supplement products. A previous study demonstrated that 12 ounces of calcium-fortified orange juice significantly decreased the bioequivalence of a dose of ciprofloxacin. This study examined, in 16 healthy volunteers, whether 12 ounces of orange juice with and without calcium fortification would demonstrate the same chelation interaction with single doses of levofloxacin. The results of the study demonstrated that both types of juice decreased levofloxacin Cmax values by 14% to 18% and prolonged tmax values by approximately 50%, with calcium-fortified orange juice decreasing Cmax enough to lose bioequivalence as compared to the control arm (89% [78.1%, 99.8%]). Due to the lack of change in overall exposure, it is thought that rather than a chelation interaction, levofloxacin and components of the orange juices competed for intestinal transport mechanisms such as P-glycoprotein and organic anion-transporting polypeptides, which resulted in the discovered interaction. These results further confirm the need to adjust regulatory studies to include bioequivalence/bioavailability studies that contain fortified foods more than high-calorie/high-fat foods to better reflect current American consumption habits.